Congratulations to Franz Babl, Ed Oakley, Stuart Dalziel, Meredith Borland and Elliot Long from the PREDICT group who have been funded for more than $3 million by the Medical Research Futures Fund to participate in the international PROMPT BOLUS study on Sepsis.
The study is an open label randomised trial comparing balanced versus normal saline fluid treatment in children with sepsis.
Australian and New Zealand sites in PREDICT will work with the US and Canada (pending funding from NIH and CIHR) to undertake this trial of 8,800 children and provide the evidence necessary to change clinical practice worldwide and in turn save thousands of children’s lives.
The trial was one of three to share in $5 million to allow Australian researchers and patients to take part in international clinical trials of new, lifesaving treatments.
We will be looking for investigators and sites to participate (13 sites funded with RA cover at all sites for 4.5 years) and look forward to sharing further news soon. For questions contact franz.babl@rch.org.au.